Video Experimental Relacionado
Updated: Jun 26, 2025
10:28
Body Composition and Metabolic Caging Analysis in High Fat Fed Mice
Published on: May 24, 2018
15.5K
Antagonismo del receptor NMDA dirigido por GLP-1 para el tratamiento de la obesidad
Jonas Petersen1,2, Mette Q Ludwig1, Vaida Juozaityte1
1Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Nature
|May 15, 2024
Resumen
Una nueva molécula bimodal combina el antagonismo del receptor de N-metil-D-aspartato (NMDA) con el agonismo del receptor de péptido tipo glucagón-1 (GLP-1). Este enfoque revierte efectivamente los síntomas de la obesidad y la enfermedad metabólica en modelos de roedores.
Área de la Ciencia:
- La neurociencia
- Investigación de las enfermedades metabólicas
- Farmacología
Sus antecedentes:
- Los receptores de N-metil-D-aspartato (NMDA) son cruciales para la función cerebral, y su modulación está relacionada con la homeostasis del peso corporal.
- La señalización de los receptores del péptido 1 parecido al glucagón (GLP-1) juega un papel en la regulación metabólica.
- Los tratamientos existentes para la obesidad y los trastornos metabólicos a menudo tienen limitaciones.
Objetivo del estudio:
- Diseñar y desarrollar una molécula bimodal que integre el antagonismo del receptor NMDA y el agonismo del receptor GLP-1.
- Investigar el potencial terapéutico de este enfoque unimolecular para la obesidad, la hiperglucemia y la dislipidemia.
- Evaluar la seguridad y eficacia del antagonismo dirigido al receptor NMDA a través de la administración del receptor GLP- 1.
Principales métodos:
- Desarrollo de una molécula bimodal que combina un antagonista del receptor NMDA (MK-801) y un agonista del receptor GLP-1.
- Utilizando la administración mediada por el receptor GLP-1 para la distribución dirigida de MK-801 a regiones cerebrales específicas.
- Evaluación preclínica en modelos de roedores de obesidad inducida por la dieta y enfermedades metabólicas.
Principales resultados:
- La molécula bimodal revertió efectivamente la obesidad, la hiperglucemia y la dislipidemia en modelos de roedores.
- La administración dirigida del antagonista del receptor NMDA a las regiones cerebrales que expresan el receptor GLP- 1 mitigó los efectos adversos asociados con la monoterapia.
- Cambios de neuroplasticidad demostrados en el hipotálamo y el tronco cerebral debido al antagonismo del receptor NMDA dirigido por GLP- 1.
Conclusiones:
- La orientación mediada por péptidos permite la modulación específica de las células de los receptores ionotrópicos.
- La combinación unimolecular de agonismo del receptor GLP-1 y antagonismo del receptor NMDA ofrece una estrategia terapéutica prometedora para la obesidad.
- Este enfoque tiene potencial para el tratamiento seguro y eficaz de las enfermedades metabólicas.
Videos de Conceptos Relacionados
01:24Glucagon-like Receptor Agonists
318
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318
01:30Regulation of Food Intake
224
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
224
01:06Oral Hypoglycemic Agents: Glinides
153
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
153
01:23Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
01:14Antiepileptic Drugs: Glutamate Antagonists
321
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
321
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192